EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pasithea Therapeutics's enterprise value is $-8.24 Mil.
Pasithea Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-15.38 Mil. Therefore, Pasithea Therapeutics's EV-to-EBITDA for today is 0.54.
The historical rank and industry rank for Pasithea Therapeutics's EV-to-EBITDA or its related term are showing as below:
KTTA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.54 Med: 4.24 Max: 13.59
Current: 0.54
During the past 4 years, the highest EV-to-EBITDA of Pasithea Therapeutics was 13.59. The lowest was 0.54. And the median was 4.24.
KTTA's EV-to-EBITDA is ranked better than 77.71% of 462
companies
in the Biotechnology industry
Industry Median: 9.49
vs KTTA: 0.54
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Pasithea Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Pasithea Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pasithea Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Pasithea Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pasithea Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pasithea Therapeutics's EV-to-EBITDA falls into.
Pasithea Therapeutics's current Enterprise Value is $-8.24 Mil.
Pasithea Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Pasithea Therapeutics's PE Ratio for today is calculated as:
Pasithea Therapeutics's share price for today is $7.6799.
Pasithea Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Pasithea Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Pasithea Therapeutics (Pasithea Therapeutics) Business Description
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KTTA has been successfully added to your 